屈公病市場－全球產業規模、佔有率、趨勢、機會和預測，按診斷、治療、最終用戶、地區和競爭格局分類，2020-2030年預測

2024年全球屈公病市值為4.9323億美元，預計2030年將以7.28%的複合年成長率成長至7.5191億美元。全球屈公病市場涵蓋了針對這種蚊媒病毒感染的治療干預措施、診斷解決方案和預防措施，這種病毒感染主要由埃及斑蚊和白紋伊蚊傳播。

主要市場促進因素

全球屈公病發生率的上升顯著推動了對診斷工具、治療手段和預防性疫苗的市場需求。疾病流行率的提高需要更廣泛的檢測和治療，加速了產品研發。

主要市場挑戰

監測能力和診斷準備的持續差距，嚴重阻礙了全球屈公病市場的成長。這項挑戰直接影響了市場發展，延誤了疾病的及時發現和有效管理，從而限制了對診斷解決方案和後續治療介入的需求。

主要市場趨勢

mRNA疫苗技術的進步代表著一個關鍵趨勢，它透過實現快速抗原鑑定和靈活的生產流程，加快了基孔肯雅疫苗的研發週期。這項技術能夠更快地應對新出現的病毒株，並有望實現高效的疫苗效力。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球屈公病市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依診斷方法（基於酵素連結免疫吸附試驗、血清學檢測、病毒學檢測）
  • 依治療方法（西醫、順勢療法、阿育吠陀療法、其他）
  • 按最終使用者（醫院和診所、門診手術護理、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美屈公病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲屈公病市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區屈公病市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲屈公病市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲屈公病市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球屈公病市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Quest Diagnostics, Inc.
• Abbott Laboratories, Inc.
• Genome Diagnostics Pvt. Ltd.
• Altona Diagnostics GmbH
• Bio-Rad Laboratories, Inc.
• Taj Pharmaceuticals Ltd.
• Etubics Corporation
• Shanghai Solve Care Co. Ltd.

第16章：策略建議

第17章調查會社について,免責事項

The Global Chikungunya Fever Market, valued at USD 493.23 Million in 2024, is projected to experience a CAGR of 7.28% to reach USD 751.91 Million by 2030. The Global Chikungunya Fever Market encompasses therapeutic interventions, diagnostic solutions, and preventive measures addressing this mosquito-borne viral infection, primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes.

Key Market Drivers

The rising global incidence of Chikungunya Fever significantly drives market demand for diagnostic tools, therapeutic interventions, and preventive vaccines. Heightened disease prevalence necessitates more widespread testing and treatment, accelerating product development. According to the European Centre for Disease Prevention and Control, as of November 2024, approximately 480,000 Chikungunya cases were reported worldwide, underscoring the expanding public health challenge.

Key Market Challenges

The persistent gap in surveillance capabilities and diagnostic readiness represents a significant impediment to the growth of the Global Chikungunya Fever Market. This challenge directly hampers the market by delaying timely detection and effective management of the disease, thereby limiting the demand for diagnostic solutions and subsequent therapeutic interventions. When infections go undetected or are misdiagnosed, the market for related products cannot expand to its full potential.

Key Market Trends

Advances in mRNA Vaccine Technology represent a pivotal trend, expediting the development cycle for Chikungunya vaccines by enabling rapid antigen identification and flexible manufacturing processes. This technology allows for quicker responses to emerging viral strains and offers the potential for high-efficacy profiles. According to *Vaccine*, in June 2023, Moderna's mRNA-1388 Chikungunya vaccine candidate demonstrated favorable safety and immunogenicity in a Phase 1 study, eliciting substantial and persistent neutralizing antibody responses in healthy adults.

Key Market Players

• Quest Diagnostics, Inc.
• Abbott Laboratories, Inc.
• Genome Diagnostics Pvt. Ltd.
• Altona Diagnostics GmbH
• Bio-Rad Laboratories, Inc.
• Taj Pharmaceuticals Ltd.
• Etubics Corporation
• Shanghai Solve Care Co. Ltd.

Report Scope:

In this report, the Global Chikungunya Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chikungunya Fever Market, By Diagnosis:

• ELISA Based Assays
• Serological Tests
• Virological Tests

Chikungunya Fever Market, By Treatment:

• Allopathy
• Homeopathy
• Ayurveda
• Others

Chikungunya Fever Market, By End User:

• Hospital & Clinics
• Ambulatory Surgical care
• Others

Chikungunya Fever Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Chikungunya Fever Market.

Available Customizations:

Global Chikungunya Fever Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chikungunya Fever Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests)
  • 5.2.2. By Treatment (Allopathy, Homeopathy, Ayurveda, Others)
  • 5.2.3. By End User (Hospital & Clinics, Ambulatory Surgical care, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Chikungunya Fever Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chikungunya Fever Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Chikungunya Fever Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Chikungunya Fever Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User

7. Europe Chikungunya Fever Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chikungunya Fever Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. France Chikungunya Fever Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Chikungunya Fever Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Chikungunya Fever Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Chikungunya Fever Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End User

8. Asia Pacific Chikungunya Fever Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Chikungunya Fever Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. India Chikungunya Fever Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Chikungunya Fever Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Chikungunya Fever Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Chikungunya Fever Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End User

9. Middle East & Africa Chikungunya Fever Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Chikungunya Fever Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Chikungunya Fever Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Chikungunya Fever Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. South America Chikungunya Fever Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Chikungunya Fever Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Chikungunya Fever Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Chikungunya Fever Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Chikungunya Fever Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Quest Diagnostics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories, Inc.
• 15.3. Genome Diagnostics Pvt. Ltd.
• 15.4. Altona Diagnostics GmbH
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. Taj Pharmaceuticals Ltd.
• 15.7. Etubics Corporation
• 15.8. Shanghai Solve Care Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer